NVCR

NovoCure Ltd

Jun 12 • 04:00PM ET

17.78

+0.07 0.40 %

Healthcare • Medical Devices • United Kingdom • Mid • NASD

Peers: IRTC MASI BSX EW MDT SYK ABT RMD BAX BDX

| Held by: VTI IWM VB VBK VXF BRES IWO IBB SCHA IHI

Index	RUT	P/E	-	EPS (ttm)	-1.53	Insider Own	10.10%	Shs Outstand	115.82M	Perf Week	3.61%
Market Cap	2.06B	Forward P/E	-	EPS next Y	-1.17	Insider Trans	-1.89%	Shs Float	104.12M	Perf Month	-1.77%
Enterprise Value	1.85B	PEG	-	EPS next Q	-0.33	Inst Own	86.22%	Short Float	8.79%	Perf Quarter	47.43%
Income	-173.05M	P/S	3.05	EPS this Y	-30.68%	Inst Trans	0.68%	Short Ratio	6.15	Perf Half Y	34.49%
Sales	674.41M	P/B	6.23	EPS next Y	26.52%	ROA	-16.99%	Short Interest	9.15M	Perf YTD	37.51%
Book/sh	2.86	P/C	4.66	EPS next 5Y	20.74%	ROE	-49.96%	52W High	18.92 -6.03%	Perf Year	-2.31%
Cash/sh	3.81	P/FCF	-	EPS past 3/5Y	-11.40% -	ROIC	-30.59%	52W Low	9.82 81.06%	Perf 3Y	-59.80%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	6.81% 5.80%	Gross Margin	75.20%	Volatility	5.74% 5.91%	Perf 5Y	-91.78%
Dividend TTM	-	EV/Sales	2.75	EPS Y/Y TTM	-1.53%	Oper. Margin	-27.19%	ATR (14)	1.03	Perf 10Y	32.59%
Dividend Ex-Date	-	Quick Ratio	2.70	Sales Y/Y TTM	8.48%	Profit Margin	-25.66%	RSI (14)	57.48	Recom	1.57
Dividend Gr. 3/5Y	- -	Current Ratio	2.90	EPS Q/Q	-100.26%	SMA20	3.04%	Beta	0.90	Target Price	26.29
Payout	-	Debt/Eq	0.71	Sales Q/Q	12.30%	SMA50	17.52%	Rel Volume	0.67	Prev Close	17.71
Employees	1605	LT Debt/Eq	0.71	Earnings	Apr 30 BMO	SMA200	34.08%	Avg Volume	1.49M	Price	17.78
IPO	Oct 02, 2015	Option/Short	Yes / Yes	EPS/Sales Surpr.	-21.05% 3.75%	Trades		Volume	992,141	Change	0.40%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-25-25	Downgrade	Wells Fargo	Overweight → Equal Weight	$14.50
Jul-08-25	Initiated	Ladenburg Thalmann	Buy	$30
Dec-02-24	Upgrade	Evercore ISI	In-line → Outperform	$18 → $30
Oct-16-24	Upgrade	H.C. Wainwright	Neutral → Buy	$24 → $30
Nov-20-23	Resumed	JP Morgan	Neutral	$15
Aug-28-23	Downgrade	H.C. Wainwright	Buy → Neutral	$85 → $25
Aug-08-23	Upgrade	Piper Sandler	Neutral → Overweight	$45
Aug-04-23	Initiated	SVB Securities	Outperform	$51
Jul-31-23	Upgrade	Evercore ISI	Underperform → In-line	$33
Jun-07-23	Upgrade	Wedbush	Underperform → Neutral	$53 → $46
May-16-23	Upgrade	Wells Fargo	Equal Weight → Overweight	$70 → $104
Mar-17-23	Downgrade	JP Morgan	Neutral → Underweight	$99 → $50
Jan-06-23	Downgrade	Wells Fargo	Overweight → Equal Weight	$89 → $107
Jan-05-23	Reiterated	H.C. Wainwright	Buy	$100 → $140
Nov-29-22	Upgrade	Wells Fargo	Equal Weight → Overweight	$74 → $89
Oct-24-22	Downgrade	Piper Sandler	Overweight → Neutral	$90 → $70
Jul-05-22	Downgrade	Evercore ISI	In-line → Underperform
May-16-22	Initiated	H.C. Wainwright	Buy	$115
Feb-08-22	Initiated	Loop Capital	Buy	$200
Feb-02-22	Upgrade	Oppenheimer	Perform → Outperform	$98

Show Previous Ratings

May-04-26 04:29PM	NovoCure Stock Shows Strength With RS Upgrade; Investors Should Watch For Next Entry (Investor's Business Daily) -6.20%
Apr-30-26 08:45PM	NovoCure Limited Q1 2026 Earnings Call Summary (Moby) +27.49% +9.27%
01:12PM	Two Medical Stocks Skyrocket After Demolishing Views - And One Is About To Break Out (Investor's Business Daily)
07:23AM	NovoCure: Q1 Earnings Snapshot (Associated Press)
07:00AM	Novocure Reports First Quarter 2026 Financial Results (Business Wire)
07:00AM	Loading…
Apr-01-26 07:00AM	Novocure to Report First Quarter 2026 Financial Results (Business Wire)
Mar-26-26 07:00AM	Novocure Announces Positive Topline Results from Phase 2 PANOVA-4 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Metastatic Pancreatic Cancer (Business Wire)
Mar-09-26 11:53AM	Novocure's Optune Lua Gets Japan Reimbursement for NSCLC Treatment (Zacks)
Mar-02-26 09:15AM	NovoCure (NVCR) Reliance on International Sales: What Investors Need to Know (Zacks)
07:00AM	Novocure Announces Optune Lua Receives Reimbursement Approval in Japan for the Treatment of Non-Small Cell Lung Cancer (Business Wire)
Feb-27-26 04:30PM	Novocure to Participate in 2026 Leerink Global Healthcare Conference (Business Wire)
Feb-26-26 04:34PM	NovoCure Limited Q4 2025 Earnings Call Summary (Moby) -8.27%
04:14PM	NovoCure Ltd (NVCR) Q4 2025 Earnings Call Highlights: Record Revenue and Strategic Growth Plans ... (GuruFocus.com)
12:15PM	NovoCure (NVCR) Reports Q4 Loss, Beats Revenue Estimates (Zacks)
09:04AM	NovoCure Q4 Earnings Call Highlights (MarketBeat)
07:39AM	Loading…
07:39AM	NovoCure: Q4 Earnings Snapshot (Associated Press Finance)
07:00AM	Novocure Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Company Update (Business Wire)
Feb-25-26 09:00AM	Immuno-Oncology Investments Accelerate as Pipeline Catalysts Multiply in 2026 (PR Newswire) +27.68%
Feb-24-26 07:00AM	Tumor Treating Fields (TTFields) Therapy to be Covered for Patients with Newly Diagnosed Glioblastoma Through British Columbia Cancer (BC Cancer) (Business Wire) +6.92%
Feb-19-26 10:00AM	Will NovoCure (NVCR) Report Negative Earnings Next Week? What You Should Know (Zacks)
Feb-17-26 11:17AM	New Treatment Modalities Are Reaching Cancers That Resisted Everything Else (PR Newswire)
10:01AM	Novocure Gains FDA Approval for Optune Pax to Treat Pancreatic Cancer (Zacks)
Feb-13-26 07:42AM	Novocures stock rises 37% on FDA clearance of pancreatic cancer treatment device (Medical Device Network) -12.29%
06:00AM	Lyell starts first-of-its-kind CAR-T trial; New coalition aims to boost European biotechs (BioPharma Dive)
Feb-12-26 05:43PM	Novocure Is Up 19%. FDA Approval Is Giving the Biotech Stock a Lift. (Barrons.com) +19.33%
04:35PM	These Stocks Are Todays Movers: AppLovin, Fastly, Micron, Cisco, QuantumScape, Novocure, AST SpaceMobile, and More (Barrons.com)
04:15PM	Stocks to Watch Thursday Recap: Cisco, McDonalds, AppLovin (The Wall Street Journal)
03:11PM	Stock Market Today: S&P 500 Breaks Key Support As Techs Pace Sell-Off; Cancer Stock Vaults (Live Coverage) (Investor's Business Daily)
11:26AM	NovoCure Stock Surges After FDA Approves Optune Pax (Benzinga)
10:07AM	Stocks to Watch Thursday: Cisco, McDonald's, AppLovin (The Wall Street Journal)
06:53AM	Loading…
06:53AM	This Biotech Stock Is Jumping 25% After Getting an FDA Boost (Barrons.com)
06:28AM	AppLovin shares slide after earnings, and other early market movers (MarketWatch)
06:19AM	Stock Market Today: Dow Jones, S&P 500 Futures Gain After Strong Job Report-Micron, Novocure, Fastly In Focus (Benzinga)
04:50AM	Stock Market Today: Dow, S&P 500 and Nasdaq point higher as tech finds its footing; Treasurys steady; precious metals dip. (MarketWatch)
Feb-11-26 09:55PM	NovoCure (NVCR) Stock Is Trending Overnight - Here's What You Should Know (Benzinga)
06:33PM	Novocure Gets FDA Approval for Pancreatic Cancer Treatment; Shares Soar (The Wall Street Journal)
05:54PM	U.S. FDA Approves Novocure's Optune Pax for the Treatment of Locally Advanced Pancreatic Cancer (Business Wire)
Feb-05-26 08:10AM	Bristol Myers Squibb (BMY) Tops Q4 Earnings and Revenue Estimates (Zacks) -12.72%
Jan-12-26 07:00AM	Novocure Announces Preliminary Full Year and Fourth Quarter 2025 Performance and Provides Company Update (Business Wire)
Jan-07-26 03:58AM	Moderna (MRNA) Soars 10.9%: Is Further Upside Left in the Stock? (Zacks)
Dec-22-25 07:00AM	Novocure to Present at 44th Annual J.P. Morgan Healthcare Conference (Business Wire)
Dec-09-25 05:31AM	Medtronic changes investor relations leadership ahead of diabetes spinout (MedTech Dive) +5.31%
Dec-01-25 07:00AM	Novocure Appoints Company President Frank Leonard as Chief Executive Officer (Business Wire) -8.82%
Nov-26-25 07:00AM	Novocure to Participate in 37th Annual Piper Sandler Healthcare Conference (Business Wire)
Nov-12-25 10:00AM	2 Healthcare Stocks for Individual Investors With a 40-Year Time Horizon (Motley Fool)
07:00AM	Novocure to Participate in 2025 Jefferies Global Healthcare Conference (Business Wire)
Oct-30-25 04:22PM	NovoCure Ltd (NVCR) Q3 2025 Earnings Call Highlights: Revenue Growth Amidst Challenges (GuruFocus.com)
10:30AM	Compared to Estimates, NovoCure (NVCR) Q3 Earnings: A Look at Key Metrics (Zacks)
08:20AM	NovoCure (NVCR) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
07:17AM	NovoCure: Q3 Earnings Snapshot (Associated Press Finance)
07:00AM	Novocure Reports Third Quarter 2025 Financial Results (Business Wire)
Oct-15-25 07:00AM	Novocure to Present New Research for Tumor Treating Fields (TTFields) Therapy at European Association of Neuro-Oncology (EANO) Meeting and the European Society for Medical Oncology (ESMO) Congress (Business Wire) +7.67%
Oct-01-25 07:00AM	Novocure to Report Third Quarter 2025 Financial Results (Business Wire) +8.20%
Sep-29-25 04:30PM	Novocure to Present Final Results from the Pivotal Phase 3 METIS Trial of its Tumor Treating Fields (TTFields) Therapy for Brain Metastases from Non-Small Cell Lung Cancer at 2025 ASTRO Annual Meeting (Business Wire)
Sep-16-25 05:28AM	Novocure obtains approval for Optune Lua device in Japan to treat NSCLC (Medical Device Network)
Sep-15-25 07:00AM	Novocure's Optune Lua Receives Approval in Japan for the Treatment of Unresectable Advanced/Recurrent Non-Small Cell Lung Cancer (NSCLC) (Business Wire)
Aug-29-25 04:26AM	2 Beaten-Down Stocks That Could Rocket 142% to 222% Higher, According to Wall Street Analysts (Motley Fool)
Aug-28-25 07:00AM	Novocure Announces Upcoming Investor Events (Business Wire)
Aug-25-25 07:00AM	Novocure Announces Coverage of Tumor Treating Fields (TTFields) Therapy for Patients with Newly Diagnosed Glioblastoma in Spain (Business Wire) -5.87%
Aug-22-25 01:37PM	NVCR Stock Slips Despite PMA Application to Treat Pancreatic Cancer (Zacks)
Aug-20-25 07:00AM	Novocure Submits Premarket Approval Application to FDA for Tumor Treating Fields Therapy in Locally Advanced Pancreatic Cancer (Business Wire)
Aug-13-25 12:08PM	Leerink Partners Reiterates a Buy Rating on NovoCure Limited (NVCR) (Insider Monkey)
Jul-25-25 07:02AM	NovoCure: Q2 Earnings Snapshot (Associated Press Finance)
Jul-24-25 01:30PM	NovoCure (NVCR) Reports Q2 Earnings: What Key Metrics Have to Say (Zacks) -24.05%
08:05AM	NovoCure (NVCR) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
07:00AM	Novocure Reports Second Quarter 2025 Financial Results (Business Wire)
Jul-01-25 07:00AM	Novocure to Present Final Secondary Endpoint Data from the Phase 3 PANOVA-3 Trial of Tumor Treating Fields (TTFields) in Pancreatic Cancer at the ESMO Gastrointestinal Cancers Congress 2025 (Business Wire)
Jun-30-25 09:32AM	NovoCure (NVCR) Soars 5.3%: Is Further Upside Left in the Stock? (Zacks)
07:00AM	Novocure to Report Second Quarter 2025 Financial Results (Business Wire)
Jun-18-25 12:00PM	What Makes NovoCure (NVCR) a New Buy Stock (Zacks)
Jun-06-25 12:26PM	NVCR Stock Dips Despite Positive OS Data From Phase 3 PANOVA-3 Trial (Zacks)
Jun-02-25 02:05PM	NovoCure's Tumor Treating Fields Boost One-Year And Pain-Free Survival In Pancreatic Cancer Trial (Benzinga) -10.83%
May-31-25 03:08PM	Zai Lab and Novocure Announce Results From the Phase 3 PANOVA-3 Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer to be Presented at 2025 ASCO Annual Meeting (Business Wire)
08:00AM	Results From the Phase 3 PANOVA-3 Trial of Novocure's Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer to be Presented at 2025 ASCO Annual Meeting (Business Wire)
May-28-25 06:57AM	1 Stock Down 35% This Year You'll Regret Not Buying on the Dip, According to Wall Street (Motley Fool)
May-27-25 07:00AM	Novocure Announces Upcoming Investor Events (Business Wire)
May-16-25 10:00AM	The Next Frontier to Treat Cancer: Electricity (The Wall Street Journal)
May-15-25 09:55AM	Does NovoCure (NVCR) Have the Potential to Rally 105.5% as Wall Street Analysts Expect? (Zacks)
Apr-29-25 09:55AM	Wall Street Analysts See a 91.92% Upside in NovoCure (NVCR): Can the Stock Really Move This High? (Zacks)
Apr-25-25 01:21PM	Why NovoCure Stock Skyrocketed This Week (Motley Fool)
Apr-24-25 07:03PM	Why NovoCure Stock Leaped 4% Higher Today (Motley Fool)
10:34AM	NovoCure Limited (NVCR) Q1 2025 Earnings Call Transcript (Seeking Alpha)
09:30AM	NovoCure (NVCR) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
08:15AM	NovoCure (NVCR) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
07:13AM	NovoCure: Q1 Earnings Snapshot (Associated Press Finance)
07:00AM	Novocure Reports First Quarter 2025 Financial Results (Business Wire)
Apr-23-25 10:16AM	Novocure to Present Results from the Phase 3 PANOVA-3 Clinical Trial of its Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer as a Late-Breaking Oral Presentation at the 2025 ASCO Annual Meeting (Business Wire) +7.63%
06:45AM	Novocures device for metastatic NSCLC treatment gains CE Mark (Medical Device Network)
Apr-22-25 10:01AM	Exelixis (EXEL) Earnings Expected to Grow: What to Know Ahead of Q1 Release (Zacks) +5.97%
07:09AM	Novocure's Optune Lua Receives CE Mark Approval for the Treatment of Metastatic Non-Small Cell Lung Cancer (Business Wire)
Apr-17-25 10:01AM	NovoCure (NVCR) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
Apr-16-25 03:43PM	Why NovoCure Stock Was Withering on Wednesday (Motley Fool)
Apr-10-25 08:40AM	Strength Seen in Bio-Techne (TECH): Can Its 10.8% Jump Turn into More Strength? (Zacks) -5.13%
Apr-01-25 07:00AM	Novocure to Report First Quarter 2025 Financial Results (Business Wire)
Mar-21-25 05:16PM	Zai Lab: Innovative Pharma Set For Strong Year Of Business (And Share Price) Growth (SeekingAlpha)
Mar-04-25 07:00AM	Novocure to Participate in Leerink Partners 2025 Global Healthcare Conference (Business Wire)
Feb-28-25 02:09AM	NovoCure Ltd (NVCR) Q4 2024 Earnings Call Highlights: Strong Revenue Growth Amidst Financial ... (GuruFocus.com)
Feb-27-25 03:30PM	NovoCure (NVCR) Q4 2024 Earnings Call Transcript (Motley Fool) -12.43%
10:00AM	NovoCure (NVCR) Reports Q4 Earnings: What Key Metrics Have to Say (Zacks)
08:20AM	NovoCure (NVCR) Reports Q4 Loss, Misses Revenue Estimates (Zacks)

NovoCure Ltd. is an oncology company which engages in the development, manufacture, and commercialization of Optune for the treatment of a variety of solid tumors. Its platform is called the Tumor Treating Field which uses electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division. The company was founded by Yoram Palti in 2000 and is headquartered in St. Helier, Jersey.

Executive ChairmanMr. William F. Doyle

Chief Executive OfficerMr. Frank Leonard

Chief Financial OfficerMr. Christoph Brackmann

Chief Human Resources OfficerMr. Michael Puri

Ph.D.Dr. Uri Weinberg M.D.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Leonard Frank X	Chief Executive Officer	Jun 04 '26	Sale	17.93	34,273	614,635	459,520	Jun 05 04:28 PM
FRANCIS LEONARD	Officer	Jun 04 '26	Proposed Sale	17.93	34,273	614,635		Jun 04 05:41 PM
LEUNG GABRIEL	Director	Jun 02 '26	Sale	15.77	2,945	46,445	89,499	Jun 03 04:54 PM
Stafford Kristin	Director	Jun 02 '26	Sale	15.77	2,945	46,445	11,324	Jun 03 04:53 PM
Ocean Allyson J	Director	Jun 02 '26	Sale	15.77	2,945	46,445	11,324	Jun 03 04:53 PM
Scannell Timothy J	Director	Jun 02 '26	Sale	15.77	2,945	46,445	14,288	Jun 03 04:53 PM
HILLEMAN JERYL L	Director	Jun 02 '26	Sale	15.77	2,945	46,445	13,861	Jun 03 04:53 PM
VERNON W ANTHONY	Director	Jun 02 '26	Sale	15.77	2,945	46,445	197,657	Jun 03 04:52 PM
Hung David	Director	Jun 02 '26	Sale	15.77	2,945	46,445	20,465	Jun 03 04:52 PM
VERNON W ANTHONY	Director	Apr 28 '26	Option Exercise	11.39	21,500	244,885	200,602	Apr 28 04:27 PM
Leupin Nicolas	Former Chief Medical Officer	Mar 04 '26	Sale	13.31	1,100	14,636	102,979	Mar 05 04:33 PM
Weinberg Uri	Chf Medical and Innovation Ofr	Mar 04 '26	Sale	13.31	6,412	85,314	267,190	Mar 05 04:32 PM
Brackmann Christoph	Chief Financial Officer	Mar 04 '26	Sale	13.31	6,412	85,314	182,842	Mar 05 04:31 PM
Leonard Frank X	Chief Executive Officer	Mar 04 '26	Sale	13.31	5,607	74,603	493,793	Mar 05 04:31 PM
Paravasthu Mukund	Chief Operating Officer	Mar 05 '26	Sale	13.77	43,246	595,670	72,832	Mar 05 04:31 PM
Paravasthu Mukund	Chief Operating Officer	Mar 04 '26	Sale	13.31	5,377	71,543	116,078	Mar 05 04:31 PM
Puri Michal Nath	Chief Human Resources Officer	Mar 04 '26	Sale	13.31	1,100	14,636	201,322	Mar 05 04:31 PM
DOYLE WILLIAM F	Executive Chairman	Mar 03 '26	Sale	12.98	71,887	932,883	328,397	Mar 05 04:30 PM
MUKUND PARAVASTHU	Officer	Mar 05 '26	Proposed Sale	13.77	43,246	595,682		Mar 05 04:06 PM
CHRISTOPH BRACKMANN	Officer	Mar 04 '26	Proposed Sale	13.31	6,412	85,314		Mar 04 05:54 PM
URI WEINBERG	Officer	Mar 04 '26	Proposed Sale	13.31	6,412	85,314		Mar 04 05:53 PM
MUKUND PARAVASTHU	Officer	Mar 04 '26	Proposed Sale	13.31	5,377	71,543		Mar 04 05:42 PM
FRANCIS LEONARD	Officer	Mar 04 '26	Proposed Sale	13.31	5,607	74,603		Mar 04 05:13 PM
WILLIAM DOYLE	Officer	Mar 03 '26	Proposed Sale	12.98	71,887	932,885		Mar 03 05:01 PM
Weinberg Uri	Chf Medical and Innovation Ofr	Feb 27 '26	Sale	13.84	7,461	103,257	213,757	Mar 03 04:11 PM
Weinberg Uri	Chf Medical and Innovation Ofr	Mar 02 '26	Sale	13.33	3,272	43,607	223,477	Mar 03 04:11 PM
Puri Michal Nath	Chief Human Resources Officer	Feb 27 '26	Sale	13.66	1,441	19,690	162,322	Mar 03 04:10 PM
Leonard Frank X	Chief Executive Officer	Feb 27 '26	Sale	13.66	9,734	133,003	338,011	Mar 03 04:09 PM
Leonard Frank X	Chief Executive Officer	Mar 02 '26	Sale	13.49	7,232	97,581	349,400	Mar 03 04:09 PM
FRANCIS LEONARD	Officer	Mar 02 '26	Proposed Sale	13.49	7,232	97,581		Mar 02 05:40 PM
URI WEINBERG	Officer	Mar 02 '26	Proposed Sale	13.33	3,272	43,607		Mar 02 04:14 PM
FRANCIS LEONARD	Officer	Feb 27 '26	Proposed Sale	13.66	9,734	133,003		Feb 27 05:13 PM
URI WEINBERG	Officer	Feb 27 '26	Proposed Sale	13.84	7,461	103,257		Feb 27 04:19 PM
Cordova Ashley	Chief Executive Officer	Sep 05 '25	Buy	12.22	81,550	996,859	437,569	Sep 08 07:10 AM
Brackmann Christoph	Chief Financial Officer	Jul 29 '25	Buy	11.59	20,000	231,800	141,150	Jul 30 04:33 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

NVCR

NovoCure Ltd

Upgrade your Finviz experience